Discussing the Supreme Court’s decision in Mayo v. Prometheus to reject two patents on a method for monitoring a patient’s blood to determine appropriate drug dosage as well as the decision’s potential to affect the profitability of personalized medicine, Partner Courtenay Brinckerhoff said the rejection is a disruption of the status quo that may result in less funding for research. First published in an article that appeared in Reuters, Ms. Brinckerhoff’s comments later appeared in additional publications including the Chicago Tribune, Yahoo! News, BioPortfolio and The Huffington Post.
People
Related News
17 April 2025
In the News
Donald Schroeder Shares Insight on Legislative Push for Gig Driver Unionization
Foley & Lardner LLP partner Donald Schroeder commented on the legislative push for gig driver unionization in the Law360 article, "Minn. Gig Driver Union Bills Raise Employee Status Concerns."
17 April 2025
In the News
Foley Attorneys Publish on International Arbitration's Role in Tariff Dispute Resolution
With the Trump administration's emphasis on tariffs, including introducing tariffs against the U.S.' three biggest trading partners and advocating for an External Revenue Service to collect tariffs and other foreign revenue, members of the business world face increasing uncertainties as they assess and renegotiate the cost of doing business and obligations under a changed economic and political landscape, increasing the likelihood of contract disputes.
16 April 2025
In the News
Vanessa Miller Assesses State of EV Market Under New Administration
Foley & Lardner LLP partner Vanessa Miller assessed the state of the electric vehicle market under the new administration in The Wall Street Journal article, "How Trump’s Policies Will Slow—but Not Kill—a Transition to Cleaner Energy."